Aureka Biotech Raises $100M Series B for Biological Foundation Models

In the competitive biotech space, Aureka's $100M raise underscores a growing conviction that the future of drug discovery lies in AI systems that don't just assist scientists but actually learn the fundamental rules of biology. For pharma and biotech executives, the company's closed-loop Lab-in-the-Loop architecture promises a tangible path to reduce attrition rates and speed up candidate selection. This funding signals that investors are betting on a platform approach, not just a pipeline of molecules.

Aureka Biotechnologies, a 2023-founded AI-native TechBio company, announced the close of a US$100 million Series B financing on August 10, 2026, bringing its total funding to nearly US$200 million. The round was structured in two tranches: an initial exclusive investment by Granite Asia, followed by a second tranche led by an unnamed prominent strategic investor, with participation from HighLight Capital (HLC) and existing backers MPCi and NRL Capital. This capital injection marks a significant milestone not just for the company but for the broader AI-driven drug discovery sector, as it underscores investor confidence in the pivot from using AI merely as a tool for efficiency toward building comprehensive biological world models that can fundamentally understand, generate, and predict complex living systems.

“

Aureka Biotechnologies, a 2023-founded AI-native TechBio company, announced the close of a US$100 million Series B financing on August 10, 2026, bringing its total funding to nearly US$200 million.

The proceeds are earmarked primarily for research and large-scale training of next-generation biological foundation models. These models aim to excel at de novo molecular design, biological structure modeling, and function prediction—core tasks that have historically required laborious trial-and-error. Aureka also plans to upgrade its ‘Lab-in-the-Loop’ experiment-centered feedback engine, which integrates single-cell functional screening, high-throughput experimental validation, and drug development platforms. This creates a tightly coupled loop where AI models propose hypotheses and learn from real-world experimental results, potentially accelerating the drug discovery cycle from years to months. The company’s infrastructure already combines large-scale pre-training, project-specific post-training, AI agents, and automated experiments into what it calls an ‘AI-for-Science’ stack—a phrase that captures the ambition to make models that do not just solve individual tasks but internalize the rules of biology.

The market context is critical: the pharmaceutical industry is grappling with Eroom’s Law, where the cost of developing a new drug doubles roughly every nine years. AI-native biotechs have been attracting massive funding rounds in hopes of breaking that curve. Aureka’s focus on a closed-loop system where dry-lab AI and wet-lab experimentation feed each other positions it alongside emerging players like Recursion, Insilico Medicine, and Generate Biomedicines—though Aureka’s emphasis on building a generalizable world model rather than a pipeline of individual drug candidates marks a philosophical divergence. If successful, such a model could be licensed across multiple therapeutic areas, creating a platform business with potentially exponential returns.